查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1835362

顱內支架市場按產品類型、材料、塗層、適應症、最終用戶和分銷管道分類－2025-2032 年全球預測

Intracranial Stents Market by Product Type, Material, Coating, Indication, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年顱內支架市場將成長 28.88 億美元，複合年成長率為 15.19%。

主要市場統計數據
預測年份（2024年） 9.0351億美元
基準年（2025年） 1,038,440,000美元
預測年份（2032年） 2,888,000美元
複合年成長率（%） 15.19%

全面介紹顱內支架，涵蓋臨床需求、設備演變、監管背景以及臨床實施的實際考慮

顱內支架是治療動脈瘤疾病和顱內狹窄的重要工具，處於工程創新與急性神經血管治療之間的關鍵交會點。過去二十年，器械設計師和介入神經放射學不斷改進支架結構、材料和置入技術，以提高其在迂曲腦血管中的可操作性，並促進長期血管重塑。這一演變反映了臨床反饋、診斷成像技術進步和製造能力之間的持續對話，三者均致力於最大限度地降低圍手術期風險，同時擴大可治療病變的範圍。

如今，臨床醫生面臨複雜的決策矩陣，需要考慮器械外形、徑向力、透視可見度、與輔助器材的兼容性等等。同時，法律規範和付款方的期望也越來越要求提供強力的臨床證據，證明器械具有持久的療效和良好的安全性。因此，開發重點正從簡單的機械支架轉向包含標靶給藥、新型合金和精密表面處理的整合解決方案。這些趨勢正在重塑器械開發流程，並改變每個外科中心的器械應用動態。

因此，理解顱內支架需要多面向的觀點，涵蓋器材層面的科學、臨床工作流程、醫院採購慣例以及不斷發展的報銷模式。對於尋求將產品策略與臨床需求相結合的相關人員，迫切需要將營運層面的洞察和監管現狀轉化為商業性可行的設計，從而在醫療系統採購限制的前提下顯著改善患者預後。

設備工程、臨床技術和商業性方法的關鍵變革將重新定義顱內支架的開發和應用

在技​​術突破與臨床實踐變革的共同推動下，顱內支架領域正在經歷變革性變革。材料創新，尤其是鎳鈦合金和鈷鉻合金加工製程的進步，使得低剖面支架能夠在保持徑向強度的同時提高輸送能力。同時，雷射切割和編織結構的改進也擴展了支架的選擇範圍，使其能夠更好地貼合病變形態。這些工程學上的進步，加上旨在調節新生內膜增生和降低血管再阻塞風險的藥物釋放型表面處理的日益普及，標誌著生物活性植入物正被更廣泛地應用。

在手術方面，影像導引導航和微導管平台的採用擴大了血管內團隊的治療範圍，使他們能夠治療更遠端、更複雜的解剖結構。這種能力的轉變迫使製造商最佳化支架的可視性、適配器以及與導流器和栓塞線圈等輔助器具的兼容性。同時，醫療保健系統正在強調基於價值的採購，並要求顯著降低併發症發生率、手術時間和下游資源利用率。因此，產品藍圖和商業策略正與可衡量的臨床和經濟終點更加緊密地結合。

最後，數位化工具和臨床醫生的直接管道正在重塑培訓、上市後監測和產品迭代。遠距監考、數位化病例庫以及數據驅動的上市後註冊系統正在加速營運商和開發商之間的反饋循環，縮短從臨床洞察到產品改進的時間。總而言之，這些轉變描繪出一個市場走向整合的、循證主導的解決方案的藍圖，這些解決方案將機械改進與生物和數位增強相結合。

2025 年關稅變化將如何重塑整個顱內支架生態系統的供應鏈、採購行為、監管計畫和商業策略

2025年關稅的徵收和貿易政策的調整，為全球供應鏈帶來了巨大的複雜性，並對顱內支架的製造、採購和定價策略產生了顯著的下游影響。依賴國際供應網路取得關鍵原料、精密合金加工和專業契約製造的製造商正面臨更高的到岸成本和更長的前置作業時間。這些壓力迫使一些相關人員重新評估籌資策略，許多企業正在加速近岸外包、雙重採購和替代供應商資格認證的計劃，以保持生產連續性並應對投入成本波動。

由於資金配置限制以及對醫療設備定價日益敏感，醫院和網路採購團隊正面臨越來越嚴格的審查。付款人和醫療系統對成本促進因素和生命週期經濟效益的透明度要求越來越高，而證明併發症發生率、再入院率和總照護成本的降低也變得日益重要。因此，製造商正透過強調基於價值的合約、延長保固期和捆綁定價模式來應對這項挑戰，這些模式旨在協調獎勵並降低採購風險。

監管和臨床研究的時間表也在根據關稅主導的不確定性進行調整。參與全球臨床臨床實驗的申辦者正在重新評估其供應計畫和緊急計畫，以確保持續供應臨床實驗設備。此外，如果關稅導致零件成本上升，規模較小的創新企業可能會感受到不成比例的負擔，迫使他們做出整合生產、尋求許可或與規模更大的現有企業合作等決策。總而言之，貿易措施的累積效應放大了供應鏈韌性、商業性靈活性以及貫穿整個產品生命週期的清晰價值主張的重要性。

可操作的細分洞察，將設備架構、材料科學、塗層生物學、適應症、最終用戶需求和分銷策略整合到一條連貫的商業化路徑中

細分市場揭示了臨床需求、技術創新和商業策略的交匯點，從而創造出差異化的價值提案。根據產品類型，市場分為球囊擴張型和自擴張式兩種結構。在自擴張式產品類別中，編織式和雷射切割式設計在性能上各有優劣，這會影響複雜解剖結構的臨床選擇。雖然球囊擴張型在精準部署和血管支架至關重要的情況下仍然適用，但自擴張式編織式設計通常在曲折的腦血管中具有卓越的順應性和血流改向特性。

鈷鉻合金、鎳鈦合金和不鏽鋼各自具有獨特的徑向強度、彈性和滲透性。鎳鈦合金因其超彈性和形狀記憶性而備受推崇，支援低調輸送和抗血管回縮性。鈷鉻合金在細支柱幾何形狀中提供高徑向力，而不銹鋼在某些適應症和製造方法中仍然是經濟高效的選擇。

塗層策略進一步提升了產品定位。當能夠耐受長期金屬-宿主相互作用時，裸金屬設計頗具吸引力，而藥物釋放型塗層則正在被探索用於減輕新生內膜增生。在藥物釋放型方法中，基於紫杉醇和Sirolimus的製劑具有獨特的生物機制和釋放動力學，從而影響了臨床試驗設計和應用模式。針對動脈瘤的器械必須同時適應動脈瘤和囊狀形態，因此需要靈活性，並且通常需要輔助的血流轉移策略。同時，狹窄介入措施需要區分動脈粥狀硬化和血栓性病因，以及抗血小板藥物和手術通訊協定。

最終用戶和分銷管道透過塑造獲取途徑和教育途徑完善了細分市場。診所和醫院的診療量和資源狀況各不相同，診療量大的三級醫療中心往往是尖端設備的早期採用者，而社區醫院則青睞經濟高效、易於部署的設備。依賴直銷的分銷策略可以透過現場人員和數位化互動提供強化臨床培訓，並結合電商管道簡化補貨流程。這些細分的綜合層面可以指導產品開發、臨床證據產生和商業化策略，使醫療設備屬性與營運商需求和採購實際情況一致。

區域資訊解釋了臨床能力、監管方法和製造生態系統的差異將如何影響美洲、歐洲/中東/非洲和亞太地區的設備採用

區域動態對顱內支架的採用、監管和製造策略有著強大的影響，因此，深入了解地域差異對於有效規劃至關重要。美洲地區神經血管中心高度集中，報銷框架成熟，這使得先進設備平台能夠早期採用，但採購委員會越來越要求提供明確的經濟價值證據，以補充臨床表現。因此，尋求在美洲地區發展的公司優先考慮嚴格的臨床數據、上市後註冊以及與COE網路的直接合作，以加速採用並為產品的迭代改進提供資訊。

歐洲、中東和非洲地區（EMEA）市場格局複雜，監管環境、報銷水準和醫院能力差異巨大。歐洲的監管趨同和強大的臨床研究生態系統鼓勵進行多中心研究，而許多市場的醫療保健支付方則注重成本效益和比較有效性研究。雖然手術量和基礎設施限制可能會減緩中東和非洲新興市場的神經介入技術應用，但仍有大量機會，可以改進低成本設備並投資有針對性的培訓項目，以提升介入神經放射學能力。

亞太地區既是製造業中心，也是快速發展的需求中心。本地製造能力、熟練介入醫師的可用性以及多樣化的報銷環境，都需要製定平衡全球產品標準與本地客製化的策略。與區域經銷商、區域臨床領導者和製造外包製造商合作可以加快產品上市速度並最佳化成本結構，而針對特定區域的臨床證據則可以提高付款人的接受度和臨床醫生的信心。在每個地區，根據當地實際情況調整監管策略、臨床證據項目和供應鏈規劃，仍然是成功進入市場和擴大規模的關鍵。

策略企業洞察重點在於現有企業、創新者和供應商如何利用臨床數據、製造夥伴關係和服務模式來獲得競爭優勢

主要企業的行動揭示了市場領導和挑戰者如何將技術能力轉化為競爭優勢。成熟的醫療設備製造商投入巨資，不斷改進合金加工製程、支架幾何形狀和輸送系統，同時透過註冊和隨機試驗累積大量臨床證據，以支持其與付款人對話。這些公司通常會投資全球培訓網路和內部現場團隊，以支援高度複雜的流程，並與主要醫療系統簽訂長期合約。

較小的創新者和新興企業往往專注於顛覆性材料、新型塗層化學或專有部署機制，以滿足特定未滿足的臨床需求。規模化發展路徑通常包括：建立有針對性的臨床證據，與大型製造商建立分銷和生產策略合作夥伴關係，或探索收購以加速發展。契約製造製造商和零件供應商透過提供精密加工、先進的精加工和塗層技術，在降低器械商業化所需的資本強度方面發揮關鍵作用。

在這種競爭格局中，成功的公司將嚴謹的臨床專案與差異化技術平台和強大的供應鏈策略相結合。豐富的智慧財產權組合、在多個司法管轄區的法規核准，以及透過註冊和績效指標證明其在現實世界中的效用，是市場領導脫穎而出的關鍵因素。此外，整合數位化培訓、遠端監考和數據主導的上市後監測的公司，更有能力縮短產品採用週期，並在不同產品世代之間保持臨床醫生的參與度。

為領導者提供可行的建議，以同步產品藍圖、供應鏈彈性、臨床證據和混合商業策略，從而加速採用

產業領導者應推行協作議程，協調產品開發、臨床策略和商業性執行，從而抓住新興機遇，同時降低系統性風險。首先，優先考慮模組化產品藍圖，以便支架結構和塗層能夠不斷迭代改進，這將降低開發風險，並透過漸進式性能改進加速臨床醫生的採用，而無需徹底重新設計平台。同時，投資於可量化安全性和下游資源利用率的受控臨床試驗和高品質註冊庫，將為付款人和醫療系統提供更強大的價值提案。

第二，透過實現關鍵合金和製造程序供應商多元化、確定二級生產地點以及協商庫存和前置作業時間協議來增強供應鏈韌性，從而應對關稅相關的中斷。考慮策略性近岸外包，並與區域製造外包合作，以降低國際貿易波動帶來的風險，並縮短關鍵市場的補貨週期。第三，採用混合市場進入模式，將大批量生產基地的直銷和數位化互動與地理覆蓋範圍的經銷商夥伴關係關係相結合，並利用電子商務解決方案進行補貨和備件維修。

最後，將商業化與強大的臨床醫生支援計劃相結合，包括實踐培訓、遠端指導以及追蹤實際表現的成果儀表板。將這些舉措與靈活的商業條款相結合，例如與結果掛鉤的合約以及與客戶共用手術和術後風險的捆綁產品。透過整合這些營運、臨床和商業性行動，領導者可以強化其市場定位，並加速其在不同醫療環境中的永續應用。

一種透明的多方法調查方法，結合臨床證據審查、相關人員訪談、供應鏈盡職調查和情境分析，以產生可操作的情報

本調查方法整合了多種證據流，確保假設和限制的透明性，同時得出嚴謹且可重複的結論。研究首先全面回顧同儕審查文獻、臨床試驗註冊和監管備案文件，以建構關於器械安全性、有效性和操作規範的基礎依證。除了此案調查方法外，還開展了針對性訪談，訪談對象包括臨床醫生、採購主管和品管官員，旨在了解現場對器械性能、培訓需求和採購標準的觀點。

透過與零件供應商、契約製造和材料專家的磋商，進行了供應鏈映射和技術實質審查調查，以確定製造限制和應對關稅中斷的可行緩解措施。該研究還納入了臨床登記和真實世界資料集的分析，以支持試驗結果並觀察縱向結局。透過交叉檢驗訪談見解、已發表的研究和監管文件進行資料三角檢驗，以確保結論反映的是趨同證據，而非孤立的軼事。

在整個過程中，我們運用情境分析來檢驗策略方案在各種交易、報銷和臨床應用假設下的韌性。方案的局限性，尤其是在出現新證據或存在地域差異的情況下，均被清晰地記錄下來，並根據信心度和需要進一步進行初步研究的領域調整了建議。這種定性和定量方法的結合，不僅能得出切實可行的結論，還能闡明每個見解的強度和來源。

簡明結論綜合了技術進步、臨床要求和商業性行為，這些將決定顱內支架領域的成功

顱內支架領域的特點是技術創新日新月異、臨床實踐日新月異，以及受貿易政策和付款方期望影響的日益複雜的商業性格局。材料、支架幾何形狀和塗層生物學的進步正在擴展介入神經放射學可用的臨床套件，而成像和微導管平台的改進則拓寬了血管內治療的解剖範圍。這些技術進步，加上對比較結果和成本透明度日益成長的需求，正在重新定義商業性成功的標準。

因此，有效的策略應將嚴謹的臨床證據產生、靈活的生產和分銷計劃以及與購買者優先順序相符的商業模式相結合。投資於持久臨床數據、靈活供應鏈和以臨床醫生為中心的培訓計畫的相關人員將最有能力將技術優勢轉化為廣泛的應用。隨著環境的不斷發展，持續監測監管變化、報銷變化和供應鏈訊號對於保持策略敏捷性並及時抓住產品差異化和市場成長的機會仍然至關重要。

目錄

第1章 引言

第2章分析方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 生物可吸收支架材料的進展可減少支架內血管再阻塞
  • 動脈瘤治療中擴大採用流量轉向器和管道栓塞裝置
  • 人工智慧引導部署系統在支架置入中的整合
  • 遠距醫療環境中微創神經介入技術的發展
  • 擴展混合手術室，將影像學和顱內手術結合起來
  • 開發具有抗血栓和抗發炎特性的下一代塗層支架
  • 加強醫療設備製造商與神經外科中心之間的策略合作
  • 新興市場新型顱內支架系統監理核准激增
  • 專注於使用患者特定的 3D 列印神經血管模型進行個人化支架設計
  • 公共醫療保健舉措對經濟高效的顱內支架的需求不斷成長

第6章：美國關稅的累積影響（2025年）

第7章：人工智慧（AI）的累積影響（2025年）

第8章顱內支架市場（依產品類型）

  • 球囊擴張型
  • 自膨脹
    • 編織
    • 雷射切割

9. 顱內支架市場（依材料）

  • 鈷鉻合金
  • 鎳鈦合金
  • 不銹鋼

10. 顱內支架市場（依塗層）

  • 裸機
  • 藥物釋放型
    • 紫杉醇
    • Sirolimus

第 11 章顱內支架市場（按適應症）

  • 動脈瘤
    • 紡錘形
    • 囊狀
  • 收縮
    • 動脈硬化
    • 血栓性

第 12 章。顱內支架市場（依最終用戶）

  • 診所
  • 醫院

13. 顱內支架市場（依通路）

  • 直銷
    • 電子商務
    • 現場銷售代表
  • 批發商
    • 全國經銷商
    • 區域經銷商

14. 顱內支架市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章顱內支架市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章顱內支架市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章競爭格局

  • 市佔率分析（2024年）
  • FPNV定位矩陣（2024年）
  • 競爭分析
    • Medtronic plc
    • Stryker Corporation
    • Cerenovus LLC
    • MicroPort Scientific Corporation
    • Terumo Corporation
    • Balt Extrusion SAS
    • Acandis GmbH
    • Phenox GmbH
    • Boston Scientific Corporation
    • InspireMD Ltd.
Product Code: MRR-43127F7279D7

The Intracranial Stents Market is projected to grow by USD 2,800.88 million at a CAGR of 15.19% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 903.51 million
Estimated Year [2025] USD 1,038.44 million
Forecast Year [2032] USD 2,800.88 million
CAGR (%) 15.19%

A comprehensive introduction to intracranial stents that frames clinical needs, device evolution, regulatory context, and practical considerations for clinical adoption

Intracranial stents occupy a critical intersection between engineering innovation and acute neurovascular care, serving as essential tools in the treatment of both aneurysmal disease and intracranial stenosis. Over the past two decades, device designers and neurointerventionalists have refined stent architecture, materials, and deployment techniques to improve navigability through tortuous cerebral vasculature and to enhance long-term vessel remodeling. This evolution reflects a continuous dialogue between clinical feedback, imaging advances, and manufacturing capabilities, with each iteration seeking to minimize periprocedural risk while expanding the spectrum of treatable lesions.

Clinicians now face a complex decision matrix that weighs device profile, radial force, visibility under fluoroscopy, and compatibility with adjunctive devices. Concurrently, regulatory frameworks and payer expectations increasingly demand robust clinical evidence demonstrating durable outcomes and favorable safety profiles. As a result, development priorities have migrated beyond simple mechanical scaffolding toward integrated solutions that incorporate targeted drug delivery, novel alloys, and refined surface treatments. These trends are reshaping device development pipelines and altering adoption dynamics across procedural centers.

Understanding intracranial stents therefore requires a multi-faceted perspective that incorporates device-level science, clinical workflows, hospital procurement practices, and evolving reimbursement paradigms. For stakeholders seeking to align product strategy with clinical need, the imperative is to translate procedural insights and regulatory realities into commercially viable designs that demonstrably improve patient outcomes while fitting within health system procurement constraints.

Key transformative shifts in device engineering, clinical technique, and commercial approaches that are redefining intracranial stent development and adoption

The landscape for intracranial stents is undergoing transformative shifts driven by converging technological breakthroughs and changes in clinical practice. Material innovations, particularly advances in nickel-titanium alloys and cobalt-chromium processing, have enabled lower-profile devices that maintain radial strength while improving deliverability; simultaneously, refinements in laser-cut and braided architectures have expanded device selection to better match lesion morphology. These engineering advances are paralleled by the increasing incorporation of drug-eluting surface treatments designed to modulate neointimal proliferation and reduce restenosis risk, indicating a broader shift toward biologically active implantables.

Procedurally, the adoption of image-guided navigation and enhanced microcatheter platforms has expanded the reach of endovascular teams, enabling treatment of more distal and complex anatomies. This shift in capability has pressured manufacturers to optimize stent visibility, conformability, and compatibility with adjunct devices such as flow diverters and embolic coils. At the same time, healthcare systems are emphasizing value-based procurement, requiring demonstrable reductions in complication rates, procedure times, and downstream resource utilization. Consequently, product roadmaps and commercial strategies are aligning more tightly with measurable clinical and economic endpoints.

Finally, digital tools and direct-to-clinician channels are reshaping how training, post-market surveillance, and product iterations occur. Remote proctoring, digital libraries of procedural cases, and data-driven post-market registries are accelerating feedback loops between operators and developers, which in turn compresses the timeline from clinical insight to product refinement. Taken together, these shifts depict a market moving toward integrated, evidence-driven solutions that combine mechanical sophistication with biological and digital enhancements.

How 2025 tariff changes are reshaping supply chains, procurement behavior, regulatory planning, and commercial strategies across the intracranial stent ecosystem

The imposition of tariffs and trade policy adjustments in 2025 has introduced material complexities across global supply chains, with measurable downstream impacts on intracranial stent manufacturing, procurement, and pricing strategies. Manufacturers that rely on international supply networks for critical raw materials, precision alloy processing, or specialized contract manufacturing face higher landed costs and extended lead times. These pressures have compelled some stakeholders to reevaluate sourcing strategies, with many accelerating plans for nearshoring, dual-sourcing, and qualification of alternative suppliers to preserve production continuity and to manage input-cost volatility.

Procurement teams within hospitals and networks are experiencing heightened scrutiny as device price sensitivity grows alongside constrained capital allocations. Payers and health systems are increasingly requesting transparency on cost drivers and lifecycle economics, heightening the importance of demonstrating reductions in complication rates, readmissions, and total cost of care. As a result, manufacturers are responding by emphasizing value-based contracting, longer-term warranties, and bundled pricing models that align incentives and mitigate procurement risk.

Regulatory and clinical research timelines have also adapted in response to tariff-driven uncertainties. Sponsors engaged in international trials are reassessing supply plans and contingency provisions to ensure continuity of investigational device availability. Moreover, smaller innovators may feel disproportionate strain when tariffs increase component costs, prompting decisions to consolidate manufacturing, pursue licensing, or partner with larger incumbent firms. In sum, the cumulative effect of trade measures is to amplify the importance of supply chain resilience, commercial flexibility, and clear value articulation across the product lifecycle.

Actionable segmentation insights that align device architectures, material science, coating biology, indications, end-user needs, and distribution strategies into coherent commercialization pathways

Segmentation reveals where clinical needs, engineering innovations, and commercial strategies intersect to create differentiated value propositions. Based on product type, the market differentiates between balloon-expandable devices and self-expanding architectures; within the self-expanding category, braided and laser-cut designs present distinct performance trade-offs that influence clinical choice for complex anatomies. Balloon-expandable constructs remain relevant where precise deployment and vessel scaffolding are paramount, while self-expanding braided designs frequently offer superior conformability and flow-modifying characteristics in tortuous cerebral vessels.

Material selection is another primary axis of differentiation, with cobalt-chromium, nickel-titanium, and stainless steel each offering unique profiles in terms of radial strength, elasticity, and radiopacity. Nickel-titanium alloys are prized for superelasticity and shape memory, which support low-profile delivery and resilience against vessel recoil; cobalt-chromium provides high radial force in thin strut geometries; and stainless steel continues to serve as a cost-effective option for specific indications and manufacturing approaches.

Coating strategies further stratify product positioning. Bare metal designs appeal where long-term metal-host interactions are acceptable, whereas drug-eluting coatings are being explored to mitigate neointimal proliferation. Within drug-eluting approaches, paclitaxel and sirolimus-based formulations offer different biological mechanisms and release kinetics, shaping clinical trial designs and adoption patterns. Indication-based segmentation differentiates aneurysm treatment from stenosis management; aneurysm-focused devices must address both fusiform and saccular morphologies, requiring flexibility and, often, adjunctive flow diversion strategies, while stenosis interventions distinguish between atherosclerotic and thrombotic etiologies that drive distinct antiplatelet and procedural protocols.

End user and distribution channels round out the segmentation picture by shaping access and education pathways. Clinics and hospitals represent different procedural volumes and resource profiles, with high-volume tertiary centers often adopting cutting-edge devices earlier, and community hospitals favoring cost-effective, easy-to-deploy options. Distribution strategies that rely on direct sales can provide intensive clinical training through field force or digital engagement and can pair e-commerce channels for streamlined replenishment, whereas distributor networks-both national and regional-offer broader geographic reach and inventory management capabilities. Taken together, these segmentation layers guide product development, clinical evidence generation, and commercialization tactics that align device attributes with operator needs and procurement realities.

Regional intelligence describing how differences in clinical capacity, regulatory approach, and manufacturing ecosystems shape device adoption across the Americas, EMEA, and Asia-Pacific

Regional dynamics exert a powerful influence on the adoption, regulation, and manufacturing strategies for intracranial stents, and a nuanced appreciation of geographic differences is essential for effective planning. In the Americas, high concentrations of specialized neurovascular centers and mature reimbursement frameworks support early adoption of sophisticated device platforms, but procurement committees increasingly demand clear evidence of economic value that complements clinical performance. Consequently, companies aiming to grow in the Americas prioritize rigorous clinical data, post-market registries, and direct engagement with center-of-excellence networks to accelerate uptake and inform iterative product improvements.

The Europe, Middle East & Africa region presents a heterogeneous landscape in which regulatory pathways, reimbursement levels, and hospital capabilities vary widely. European regulatory convergence and strong clinical research ecosystems facilitate multi-center studies, while healthcare payors in many markets emphasize cost-effectiveness and comparative effectiveness research. In emerging markets across the Middle East and Africa, constrained procedural volumes and infrastructure limitations can slow adoption, yet there are significant opportunities to tailor lower-cost device variants and to invest in targeted training programs that expand capacity for neurointerventional procedures.

Asia-Pacific represents both a manufacturing hub and a rapidly evolving demand center, with several countries demonstrating accelerated adoption driven by growing neurosurgical capacity and expanding health system investment. Local manufacturing capabilities, availability of skilled interventionalists, and diverse reimbursement environments require strategies that balance global product standards with regional customization. Partnerships with regional distributors, local clinical leaders, and contract manufacturers can shorten time-to-market and optimize cost structures, while region-specific clinical evidence can bolster payer acceptance and clinician confidence. Across all regions, aligning regulatory strategy, clinical evidence programs, and supply chain planning to local realities remains a cornerstone of successful market entry and scaling.

Strategic company insights highlighting how incumbents, innovators, and suppliers are leveraging clinical data, manufacturing partnerships, and service models to secure competitive advantage

Key company behaviors reveal how market leaders and challengers are translating technical capabilities into competitive advantage. Established device manufacturers concentrate investments on iterative improvements to alloy processing, stent geometry, and delivery systems, while cultivating extensive clinical evidence through registries and randomized trials to underpin payer conversations. These firms often invest in global training networks and in-house field force capabilities to support high-complexity procedures and to secure long-term contracts with major health systems.

Smaller innovators and start-ups tend to specialize in disruptive materials, novel coating chemistries, or unique deployment mechanisms that address specific unmet clinical needs. Their pathways to scale typically involve building targeted clinical evidence, pursuing strategic partnerships with larger manufacturers for distribution and production, or seeking acquisition as an acceleration route. Contract manufacturers and component suppliers play a critical enabling role by offering precision machining, advanced finishing, and coating capabilities, thereby lowering the capital intensity required for device commercialization.

Across the competitive landscape, successful companies combine rigorous clinical programs with differentiated technical platforms and resilient supply chain strategies. Intellectual property portfolios, regulatory clearances in multiple jurisdictions, and the ability to demonstrate real-world clinical utility through registries and performance metrics are decisive factors that separate market leaders from the rest. Moreover, firms that integrate digital training, remote proctoring, and data-driven post-market surveillance are better positioned to shorten adoption cycles and to maintain clinician engagement over successive product generations.

Actionable recommendations for leaders to synchronize product roadmaps, supply chain resilience, clinical evidence, and hybrid commercial strategies to accelerate adoption

Industry leaders should pursue a coordinated agenda that aligns product development, clinical strategy, and commercial execution to capture emerging opportunities while mitigating systemic risks. First, prioritize modular product roadmaps that allow iterative improvements to stent architecture and coatings without requiring full platform redesigns; this reduces development risk and accelerates clinician adoption through incremental performance gains. Concurrently, invest in comparative clinical studies and high-quality registries that quantify both safety and downstream resource utilization, enabling stronger value propositions for payers and health systems.

Second, build supply chain resilience by diversifying suppliers for critical alloys and manufacturing steps, qualifying secondary production sites, and negotiating inventory and lead-time agreements that accommodate tariff-related disruptions. Consider strategic nearshoring or partnerships with regional contract manufacturers to reduce exposure to international trade volatility and to shorten replenishment cycles for key markets. Third, adopt hybrid go-to-market models that blend direct sales and digital engagement for high-volume centers with distributor partnerships that ensure geographic reach, leveraging e-commerce solutions for replenishment and service parts.

Finally, align commercialization with a robust clinician support program that includes hands-on training, remote mentoring, and outcomes dashboards to track real-world performance. Pair these initiatives with flexible commercial terms such as outcome-linked contracts or bundled offerings that share procedural and post-procedural risk with customers. By integrating these operational, clinical, and commercial actions, leaders can strengthen market positioning and accelerate sustainable adoption across diverse healthcare environments.

A transparent, multi-method research methodology integrating clinical evidence review, stakeholder interviews, supply chain diligence, and scenario analysis to produce actionable intelligence

The research approach synthesizes multiple evidence streams to produce rigorous, reproducible conclusions while ensuring transparency in assumptions and limitations. The methodology begins with a comprehensive review of peer-reviewed literature, clinical trial registries, and regulatory filings to assemble a foundational evidence base regarding device safety, efficacy, and procedural practices. This desk-based phase is complemented by targeted interviews with clinicians, procurement leaders, and quality officers to capture frontline perspectives on device performance, training needs, and purchasing criteria.

Supply chain mapping and technical due diligence were conducted through consultations with component suppliers, contract manufacturers, and materials experts to verify manufacturing constraints and to identify feasible mitigation strategies for tariff disruptions. The research also incorporated analyses of clinical registries and real-world datasets where available to corroborate trial findings and to observe longitudinal outcomes. Data triangulation occurred through cross-validation of interview insights, published studies, and regulatory documents to ensure that conclusions reflect convergent evidence rather than isolated anecdotes.

Throughout the process, scenario analysis was used to test the resilience of strategic options under different trade, reimbursement, and clinical-adoption assumptions. Limitations were explicitly documented, particularly where evidence was emerging or geographically variable, and recommendations were calibrated to reflect areas of high confidence versus those requiring additional primary research. This blended qualitative and quantitative approach produces actionable intelligence while preserving clarity about the strength and provenance of each insight.

A concise conclusion synthesizing the technical advances, clinical imperatives, and commercial actions that will determine success in the intracranial stent arena

The intracranial stent landscape is characterized by rapid technical innovation, shifting clinical practices, and an increasingly complex commercial context shaped by trade policy and payer expectations. Advances in materials, stent geometry, and coating biology are expanding the clinical toolkit available to neurointerventionalists, while improvements in imaging and microcatheter platforms are broadening the anatomical reach of endovascular therapy. These technical advances, coupled with heightened requirements for comparative outcomes and cost transparency, are redefining commercial success criteria.

Effective strategies will therefore blend rigorous clinical evidence generation with resilient manufacturing and distribution plans, and with commercial models aligned to purchaser priorities. Stakeholders that invest in durable clinical data, flexible supply chains, and clinician-centric training programs will be best positioned to convert technical advantages into widespread adoption. As the environment continues to evolve, ongoing monitoring of regulatory shifts, reimbursement changes, and supply chain signals will remain essential to maintain strategic agility and to seize timely opportunities for product differentiation and market growth.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Advancement in bioresorbable stent materials for reduced in-stent restenosis
  • 5.2. Rising adoption of flow diverters and pipeline embolization devices for aneurysm treatment
  • 5.3. Integration of artificial intelligence-guided deployment systems in stent placement
  • 5.4. Growth of minimally invasive neurointerventional techniques in remote healthcare settings
  • 5.5. Expansion of hybrid operating suites for combined imaging and surgical intracranial procedures
  • 5.6. Development of next-generation coated stents with dual antithrombotic and anti-inflammatory properties
  • 5.7. Increasing strategic collaborations between device manufacturers and neurosurgical centers
  • 5.8. Surge in regulatory approvals of novel intracranial stent systems in emerging markets
  • 5.9. Focus on personalized stent designs using patient-specific 3D printed neurovascular models
  • 5.10. Rising demand for cost-effective intracranial stents in public healthcare initiatives

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Intracranial Stents Market, by Product Type

  • 8.1. Balloon Expandable
  • 8.2. Self Expanding
    • 8.2.1. Braided
    • 8.2.2. Laser Cut

9. Intracranial Stents Market, by Material

  • 9.1. Cobalt Chromium
  • 9.2. Nickel Titanium
  • 9.3. Stainless Steel

10. Intracranial Stents Market, by Coating

  • 10.1. Bare Metal
  • 10.2. Drug Eluting
    • 10.2.1. Paclitaxel
    • 10.2.2. Sirolimus

11. Intracranial Stents Market, by Indication

  • 11.1. Aneurysm
    • 11.1.1. Fusiform
    • 11.1.2. Saccular
  • 11.2. Stenosis
    • 11.2.1. Atherosclerotic
    • 11.2.2. Thrombotic

12. Intracranial Stents Market, by End User

  • 12.1. Clinics
  • 12.2. Hospitals

13. Intracranial Stents Market, by Distribution Channel

  • 13.1. Direct Sales
    • 13.1.1. E Commerce
    • 13.1.2. Field Force
  • 13.2. Distributor
    • 13.2.1. National Distributors
    • 13.2.2. Regional Distributors

14. Intracranial Stents Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Intracranial Stents Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Intracranial Stents Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Medtronic plc
    • 17.3.2. Stryker Corporation
    • 17.3.3. Cerenovus LLC
    • 17.3.4. MicroPort Scientific Corporation
    • 17.3.5. Terumo Corporation
    • 17.3.6. Balt Extrusion S.A.S.
    • 17.3.7. Acandis GmbH
    • 17.3.8. Phenox GmbH
    • 17.3.9. Boston Scientific Corporation
    • 17.3.10. InspireMD Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL INTRACRANIAL STENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY MATERIAL, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY MATERIAL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY COATING, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY COATING, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS INTRACRANIAL STENTS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA INTRACRANIAL STENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA INTRACRANIAL STENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA INTRACRANIAL STENTS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE INTRACRANIAL STENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST INTRACRANIAL STENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA INTRACRANIAL STENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC INTRACRANIAL STENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN INTRACRANIAL STENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC INTRACRANIAL STENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION INTRACRANIAL STENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS INTRACRANIAL STENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 INTRACRANIAL STENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO INTRACRANIAL STENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. INTRACRANIAL STENTS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. INTRACRANIAL STENTS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. INTRACRANIAL STENTS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL INTRACRANIAL STENTS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL INTRACRANIAL STENTS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY BALLOON EXPANDABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY BALLOON EXPANDABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY BALLOON EXPANDABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY BALLOON EXPANDABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY BALLOON EXPANDABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY BALLOON EXPANDABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY SELF EXPANDING, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY SELF EXPANDING, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY SELF EXPANDING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY SELF EXPANDING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY SELF EXPANDING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY SELF EXPANDING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY SELF EXPANDING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY SELF EXPANDING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY BRAIDED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY BRAIDED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY BRAIDED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY BRAIDED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY BRAIDED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY BRAIDED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY LASER CUT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY LASER CUT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY LASER CUT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY LASER CUT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY LASER CUT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY LASER CUT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY COBALT CHROMIUM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY COBALT CHROMIUM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY COBALT CHROMIUM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY COBALT CHROMIUM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY COBALT CHROMIUM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY COBALT CHROMIUM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY NICKEL TITANIUM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY NICKEL TITANIUM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY NICKEL TITANIUM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY NICKEL TITANIUM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY NICKEL TITANIUM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY NICKEL TITANIUM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY STAINLESS STEEL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY STAINLESS STEEL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY STAINLESS STEEL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY STAINLESS STEEL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY STAINLESS STEEL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY STAINLESS STEEL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY COATING, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY COATING, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY BARE METAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY BARE METAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY BARE METAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY BARE METAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY BARE METAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY BARE METAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY DRUG ELUTING, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY DRUG ELUTING, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY DRUG ELUTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY DRUG ELUTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY DRUG ELUTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY DRUG ELUTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY DRUG ELUTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY DRUG ELUTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY PACLITAXEL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY PACLITAXEL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY PACLITAXEL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY PACLITAXEL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY PACLITAXEL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY PACLITAXEL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY SIROLIMUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY SIROLIMUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY SIROLIMUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY SIROLIMUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY SIROLIMUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY SIROLIMUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY ANEURYSM, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY ANEURYSM, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY ANEURYSM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY ANEURYSM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY ANEURYSM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY ANEURYSM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY ANEURYSM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY ANEURYSM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY FUSIFORM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY FUSIFORM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY FUSIFORM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY FUSIFORM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY FUSIFORM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY FUSIFORM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY SACCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY SACCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY SACCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY SACCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY SACCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY SACCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY STENOSIS, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY STENOSIS, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY STENOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY STENOSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY STENOSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY STENOSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY STENOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY STENOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY ATHEROSCLEROTIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY ATHEROSCLEROTIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY ATHEROSCLEROTIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY ATHEROSCLEROTIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY ATHEROSCLEROTIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY ATHEROSCLEROTIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY THROMBOTIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY THROMBOTIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY THROMBOTIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY THROMBOTIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY THROMBOTIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY THROMBOTIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY DIRECT SALES, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY DIRECT SALES, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY DIRECT SALES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY DIRECT SALES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY E COMMERCE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY E COMMERCE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY E COMMERCE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY E COMMERCE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY E COMMERCE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY E COMMERCE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY FIELD FORCE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY FIELD FORCE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY FIELD FORCE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY FIELD FORCE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY FIELD FORCE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY FIELD FORCE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY DISTRIBUTOR, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY DISTRIBUTOR, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY DISTRIBUTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY DISTRIBUTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY DISTRIBUTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY DISTRIBUTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY DISTRIBUTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY DISTRIBUTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY NATIONAL DISTRIBUTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY NATIONAL DISTRIBUTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY NATIONAL DISTRIBUTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY NATIONAL DISTRIBUTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY NATIONAL DISTRIBUTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY NATIONAL DISTRIBUTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY REGIONAL DISTRIBUTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY REGIONAL DISTRIBUTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY REGIONAL DISTRIBUTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY REGIONAL DISTRIBUTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY REGIONAL DISTRIBUTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY REGIONAL DISTRIBUTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS INTRACRANIAL STENTS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS INTRACRANIAL STENTS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS INTRACRANIAL STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS INTRACRANIAL STENTS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS INTRACRANIAL STENTS MARKET SIZE, BY SELF EXPANDING, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS INTRACRANIAL STENTS MARKET SIZE, BY SELF EXPANDING, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS INTRACRANIAL STENTS MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS INTRACRANIAL STENTS MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS INTRACRANIAL STENTS MARKET SIZE, BY COATING, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS INTRACRANIAL STENTS MARKET SIZE, BY COATING, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS INTRACRANIAL STENTS MARKET SIZE, BY DRUG ELUTING, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS INTRACRANIAL STENTS MARKET SIZE, BY DRUG ELUTING, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS INTRACRANIAL STENTS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS INTRACRANIAL STENTS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS INTRACRANIAL STENTS MARKET SIZE, BY ANEURYSM, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS INTRACRANIAL STENTS MARKET SIZE, BY ANEURYSM, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS INTRACRANIAL STENTS MARKET SIZE, BY STENOSIS, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS INTRACRANIAL STENTS MARKET SIZE, BY STENOSIS, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS INTRACRANIAL STENTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS INTRACRANIAL STENTS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS INTRACRANIAL STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS INTRACRANIAL STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS INTRACRANIAL STENTS MARKET SIZE, BY DIRECT SALES, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS INTRACRANIAL STENTS MARKET SIZE, BY DIRECT SALES, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS INTRACRANIAL STENTS MARKET SIZE, BY DISTRIBUTOR, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS INTRACRANIAL STENTS MARKET SIZE, BY DISTRIBUTOR, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA INTRACRANIAL STENTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA INTRACRANIAL STENTS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA INTRACRANIAL STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. NORTH AMERICA INTRACRANIAL STENTS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA INTRACRANIAL STENTS MARKET SIZE, BY SELF EXPANDING, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA INTRACRANIAL STENTS MARKET SIZE, BY SELF EXPANDING, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA INTRACRANIAL STENTS MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA INTRACRANIAL STENTS MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA INTRACRANIAL STENTS MARKET SIZE, BY COATING, 2018-2024 (USD MILLION)
  • TABLE 216. NORTH AMERICA INTRACRANIAL STENTS MARKET SIZE, BY COATING, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA INTRACRANIAL STENTS MARKET SIZE, BY DRUG ELUTING, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA INTRACRANIAL STENTS MARKET SIZE, BY DRUG ELUTING, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA INTRACRANIAL STENTS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA INTRACRANIAL STENTS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA INTRACRANIAL STENTS MARKET SIZE, BY ANEURYSM, 2018-2024 (USD MILLION)
  • TABLE 222. NORTH AMERICA INTRACRANIAL STENTS MARKET SIZE, BY ANEURYSM, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA INTRACRANIAL STENTS MARKET SIZE, BY STENOSIS, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA INTRACRANIAL STENTS MARKET SIZE, BY STENOSIS, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA INTRACRANIAL STENTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA INTRACRANIAL STENTS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA INTRACRANIAL STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA INTRACRANIAL STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA INTRACRANIAL STENTS MARKET SIZE, BY DIRECT SALES, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA INTRACRANIAL STENTS MARKET SIZE, BY DIRECT SALES, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA INTRACRANIAL STENTS MARKET SIZE, BY DISTRIBUTOR, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA INTRACRANIAL STENTS MARKET SIZE, BY DISTRIBUTOR, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA INTRACRANIAL STENTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA INTRACRANIAL STENTS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA INTRACRANIAL STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. LATIN AMERICA INTRACRANIAL STENTS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA INTRACRANIAL STENTS MARKET SIZE, BY SELF EXPANDING, 2018-2024 (USD MILLION)
  • TABLE 238. LATIN AMERICA INTRACRANIAL STENTS MARKET SIZE, BY SELF EXPANDING, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA INTRACRANIAL STENTS MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA INTRACRANIAL STENTS MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA INTRACRANIAL STENTS MARKET SIZE, BY COATING, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA INTRACRANIAL STENTS MARKET SIZE, BY COATING, 2025-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA INTRACRANIAL STENTS MARKET SIZE, BY DRUG ELUTING, 2018-2024 (USD MILLION)
  • TABLE 244. LATIN AMERICA INTRACRANIAL STENTS MARKET SIZE, BY DRUG ELUTING, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA INTRACRANIAL STENTS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA INTRACRANIAL STENTS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA INTRACRANIAL STENTS MARKET SIZE, BY ANEURYSM, 2018-2024 (USD MILLION)
  • TABLE 248. LATIN AMERICA INTRACRANIAL STENTS MARKET SIZE, BY ANEURYSM, 2025-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA INTRACRANIAL STENTS MARKET SIZE, BY STENOSIS, 2018-2024 (USD MILLION)
  • TABLE 250. LATIN AMERICA INTRACRANIAL STENTS MARKET SIZE, BY STENOSIS, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA INTRACRANIAL STENTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA INTRACRANIAL STENTS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA INTRACRANIAL STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA INTRACRANIAL STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA INTRACRANIAL STENTS MARKET SIZE, BY DIRECT SALES, 2018-2024 (USD MILLION)
  • TABLE 256. LATIN AMERICA INTRACRANIAL STENTS MARKET SIZE, BY DIRECT SALES, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA INTRACRANIAL STENTS MARKET SIZE, BY DISTRIBUTOR, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA INTRACRANIAL STENTS MARKET SIZE, BY DISTRIBUTOR, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA INTRACRANIAL STENTS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA INTRACRANIAL STENTS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA INTRACRANIAL STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA INTRACRANIAL STENTS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA INTRACRANIAL STENTS MARKET SIZE, BY SELF EXPANDING, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA INTRACRANIAL STENTS MARKET SIZE, BY SELF EXPANDING, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA INTRACRANIAL STENTS MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA INTRACRANIAL STENTS MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA INTRACRANIAL STENTS MARKET SIZE, BY COATING, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA INTRACRANIAL STENTS MARKET SIZE, BY COATING, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA INTRACRANIAL STENTS MARKET SIZE, BY DRUG ELUTING, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA INTRACRANIAL STENTS MARKET SIZE, BY DRUG ELUTING, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA INTRACRANIAL STENTS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA INTRACRANIAL STENTS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA INTRACRANIAL STENTS MARKET SIZE, BY ANEURYSM, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA INTRACRANIAL STENTS MARKET SIZE, BY ANEURYSM, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA INTRACRANIAL STENTS MARKET SIZE, BY STENOSIS, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA INTRACRANIAL STENTS MARKET SIZE, BY STENOSIS, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA INTRACRANIAL STENTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA INTRACRANIAL STENTS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA INTRACRANIAL STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA INTRACRANIAL STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA INTRACRANIAL STENTS MARKET SIZE, BY DIRECT SALES, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA INTRACRANIAL STENTS MARKET SIZE, BY DIRECT SALES, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA INTRACRANIAL STENTS MARKET SIZE, BY DISTRIBUTOR, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA INTRACRANIAL STENTS MARKET SIZE, BY DISTRIBUTOR, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE INTRACRANIAL STENTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE INTRACRANIAL STENTS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE INTRACRANIAL STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE INTRACRANIAL STENTS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE INTRACRANIAL STENTS MARKET SIZE, BY SELF EXPANDING, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE INTRACRANIAL STENTS MARKET SIZE, BY SELF EXPANDING, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE INTRACRANIAL STENTS MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE INTRACRANIAL STENTS MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE INTRACRANIAL STENTS MARKET SIZE, BY COATING, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE INTRACRANIAL STENTS MARKET SIZE, BY COATING, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE INTRACRANIAL STENTS MARKET SIZE, BY DRUG ELUTING, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE INTRACRANIAL STENTS MARKET SIZE, BY DRUG ELUTING, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE INTRACRANIAL STENTS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE INTRACRANIAL STENTS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPE INTRACRANIAL STENTS MARKET SIZE, BY ANEURYSM, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPE INTRACRANIAL STENTS MARKET SIZE, BY ANEURYSM, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE INTRACRANIAL STENTS MARKET SIZE, BY STENOSIS, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE INTRACRANIAL STENTS MARKET SIZE, BY STENOSIS, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE INTRACRANIAL STENTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE INTRACRANIAL STENTS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPE INTRACRANIAL STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPE INTRACRANIAL STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 307. EUROPE INTRACRANIAL STENTS MARKET SIZE, BY DIRECT SALES, 2018-2024 (USD MILLION)
  • TABLE 308. EUROPE INTRACRANIAL STENTS MARKET SIZE, BY DIRECT SALES, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPE INTRACRANIAL STENTS MARKET SIZE, BY DISTRIBUTOR, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPE INTRACRANIAL STENTS MARKET SIZE, BY DISTRIBUTOR, 2025-2032 (USD MILLION)
  • TABLE 311. MIDDLE EAST INTRACRANIAL STENTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 312. MIDDLE EAST INTRACRANIAL STENTS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 313. MIDDLE EAST INTRACRANIAL STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 314. MIDDLE EAST INTRACRANIAL STENTS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 315. MIDDLE EAST INTRACRANIAL STENTS MARKET SIZE, BY SELF EXPANDING, 2018-2024 (USD MILLION)
  • TABLE 316. MIDDLE EAST INTRACRANIAL STENTS MARKET SIZE, BY SELF EXPANDING, 2025-2032 (USD MILLION)
  • TABLE 317. MIDDLE EAST INTRACRANIAL STENTS MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 318. MIDDLE EAST INTRACRANIAL STENTS MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 319. MIDDLE EAST INTRACRANIAL STENTS MARKET SIZE, BY COATING, 2018-2024 (USD MILLION)
  • TABLE 320. MIDDLE EAST INTRACRANIAL STENTS MARKET SIZE, BY COATING, 2025-2032 (USD MILLION)
  • TABLE 321. MIDDLE EAST INTRACRANIAL STENTS MARKET SIZE, BY DRUG ELUTING, 2018-2024 (USD MILLION)
  • TABLE 322. MIDDLE EAST INTRACRANIAL STENTS MARKET SIZE, BY DRUG ELUTING, 2025-2032 (USD MILLION)
  • TABLE 323. MIDDLE EAST INTRACRANIAL STENTS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 324. MIDDLE EAST INTRACRANIAL STENTS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 325. MIDDLE EAST INTRACRANIAL STENTS MARKET SIZE, BY ANEURYSM, 2018-2024 (USD MILLION)
  • TABLE 326. MIDDLE EAST INTRACRANIAL STENTS MARKET SIZE, BY ANEURYSM, 2025-2032 (USD MILLION)
  • TABLE 327. MIDDLE EAST INTRACRANIAL STENTS MARKET SIZE, BY STENOSIS, 2018-2024 (USD MILLION)
  • TABLE 328. MIDDLE EAST INTRACRANIAL STENTS MARKET SIZE, BY STENOSIS, 2025-2032 (USD MILLION)
  • TABLE 329. MIDDLE EAST INTRACRANIAL STENTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 330. MIDDLE EAST INTRACRANIAL STENTS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 331. MIDDLE EAST INTRACRANIAL STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 332. MIDDLE EAST INTRACRANIAL STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025